Agenus Inc. (NASDAQ:AGEN) Given Average Recommendation of "Hold" by Brokerages

Key Points

• Agenus Inc. has received a consensus recommendation of "Hold" from five brokerages, with an average target price of $14.50 for the stock.
• Institutional investors currently own 61.46% of Agenus' stock, with several firms purchasing new stakes in the company during the second quarter of this year.
• The biotechnology company reported a quarterly loss of ($1.00) EPS, missing analysts' estimates and falling short of revenue expectations at $25.70 million.

Shares of Agenus Inc. (NASDAQ:AGEN - Get Free Report) have received a consensus recommendation of "Hold" from the five brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $14.50.

A number of research firms recently weighed in on AGEN. Zacks Research raised shares of Agenus to a "hold" rating in a research report on Tuesday, August 12th. Weiss Ratings restated a "sell (d-)" rating on shares of Agenus in a research note on Saturday, September 27th. Wall Street Zen downgraded shares of Agenus from a "buy" rating to a "hold" rating in a research note on Sunday, August 17th. Finally, HC Wainwright reiterated a "buy" rating and set a $23.00 price objective on shares of Agenus in a research note on Wednesday, September 10th.

Institutional Trading of Agenus

Institutional investors and hedge funds have recently modified their holdings of the stock. Catalyst Funds Management Pty Ltd purchased a new stake in Agenus during the 2nd quarter valued at about $50,000. Jump Financial LLC purchased a new stake in shares of Agenus in the 2nd quarter valued at approximately $55,000. Savant Capital LLC purchased a new stake in shares of Agenus in the 2nd quarter valued at approximately $73,000. Bank of Montreal Can purchased a new stake in shares of Agenus in the 2nd quarter valued at approximately $75,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Agenus in the 2nd quarter valued at approximately $85,000. Hedge funds and other institutional investors own 61.46% of the company's stock.

Agenus Stock Performance

Shares of AGEN traded up $0.20 during midday trading on Friday, hitting $4.14. 826,674 shares of the company traded hands, compared to its average volume of 458,982. Agenus has a 52 week low of $1.38 and a 52 week high of $7.34. The firm has a 50 day moving average of $4.59 and a 200-day moving average of $4.04. The stock has a market cap of $131.90 million, a price-to-earnings ratio of -0.58 and a beta of 1.43.

Agenus (NASDAQ:AGEN - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($1.00) EPS for the quarter, missing analysts' consensus estimates of ($0.78) by ($0.22). The company had revenue of $25.70 million for the quarter, compared to analysts' expectations of $49.71 million. Sell-side analysts predict that Agenus will post -12.55 earnings per share for the current fiscal year.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.